Literature DB >> 8349151

Uterine leiomyosarcoma and endometrial stromal sarcoma: lymph node metastases and sites of recurrence.

B A Goff1, L W Rice, D Fleischhacker, H G Muntz, S S Falkenberry, N Nikrui, A F Fuller.   

Abstract

This study was undertaken to examine the incidence and conditions under which lymph node metastases are present and patterns of recurrence in women with uterine leiomyosarcoma (LMS) and endometrial stromal sarcoma (ESS), excluding malignant mixed mesodermal tumors. From 1981 through 1991, 21 women with LMS and 10 women with ESS were treated. Retroperitoneal lymph node dissections were performed in 15 women with LMS and 7 women with ESS. In the women with LMS, 4/15 (26.7%) had lymph node metastases; in each there was disseminated intra-abdominal disease. In the 7 women with ESS, there were no lymph node metastases present. Ten women (47%) with LMS developed recurrences, and 3 (14%) had persistent disease. In the 10 women with ESS, 3 (30%) had recurrences, and 1 (10%) had persistent disease. In total, recurrences involved the lung in 84% of cases. Of the 13 women with recurrences, 7 had undergone lymph node sampling, and all were negative; 4 additional women had no evidence of adenopathy on abdominal-pelvic CT scan. Lymph node metastases were found only with extrauterine disease, and in all of these cases there was rapid progression of the sarcoma. Women without extrauterine disease did not have lymph node metastases detected; however, there was still a high rate (40%) of distant failure. Knowledge of lymph node status had minimal impact on the clinical management of women with uterine LMS and ESS.

Entities:  

Mesh:

Year:  1993        PMID: 8349151     DOI: 10.1006/gyno.1993.1172

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  22 in total

Review 1.  A review of treatment of uterine leiomyosarcomas.

Authors:  Nicholas Reed
Journal:  Curr Oncol Rep       Date:  2013-12       Impact factor: 5.075

Review 2.  Gynecologic Cancer InterGroup (GCIG) consensus review: uterine and ovarian leiomyosarcomas.

Authors:  Martee L Hensley; Brigitte A Barrette; Klaus Baumann; David Gaffney; Anne L Hamilton; Jae-Weon Kim; Johanna U Maenpaa; Patricia Pautier; Nadeem Ahmad Siddiqui; Anneke M Westermann; Isabelle Ray-Coquard
Journal:  Int J Gynecol Cancer       Date:  2014-11       Impact factor: 3.437

Review 3.  Current and future options in the management and treatment of uterine sarcoma.

Authors:  Khalid El-Khalfaoui; Andreas du Bois; Florian Heitz; Christian Kurzeder; Jalid Sehouli; Philipp Harter
Journal:  Ther Adv Med Oncol       Date:  2014-01       Impact factor: 8.168

4.  Uterine Sarcomas: Experience from a Tertiary Cancer Care Center from India.

Authors:  Syed Nusrath; Sandeep Bafna; R Rajagopalan; Subramanyeshwar Rao Thammineedi; K V V N Raju; Sujit Chyau Patnaik; Satish Pawar; Yugandhar Reddy; Ramachandra Nagaraju Chavali; Sudha S Murthy
Journal:  Indian J Surg Oncol       Date:  2019-01-05

5.  [Relapsing uterine leiomyosarcoma: report of a case].

Authors:  Youssef Benabdejlil; Mohammed Elmarjany; Abdellah Babahabib; Mehdi Elhassani; Hafsa Chahdi; Jaouad Kouach; Driss Rahali Moussaoui; Mohammed Dehayni
Journal:  Pan Afr Med J       Date:  2014-09-24

6.  [Uterine sarcoma treatment].

Authors:  G Köhler
Journal:  Pathologe       Date:  2009-07       Impact factor: 1.011

7.  Undifferentiated uterine sarcoma metastatic to the brain.

Authors:  Douglas L Stofko
Journal:  Surg Neurol Int       Date:  2013-09-27

8.  Clinical Characteristics, Surgical Management and Adjuvant Therapy of Patients with Uterine Leiomyosarcoma: 27 Years of Experience.

Authors:  R Rothmund; M Huebner; C Joachim; A Hartkopf; T Fehm; M Bamberg; M Wallwiener; S Brucker; F A Taran
Journal:  Geburtshilfe Frauenheilkd       Date:  2011-12       Impact factor: 2.915

Review 9.  Uterine/female genital sarcomas.

Authors:  M L Hensley
Journal:  Curr Treat Options Oncol       Date:  2000-06

10.  Uterine leiomyosarcoma: 14-year two-center experience of 31 cases.

Authors:  Woo Young Kim; Suk-Joon Chang; Ki-Hong Chang; Jong-Hyuck Yoon; Jang Hee Kim; Byoung-Gie Kim; Duk-Soo Bae; Hee-Sug Ryu
Journal:  Cancer Res Treat       Date:  2009-03-31       Impact factor: 4.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.